
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is well-positioned for revenue growth due to its advancing collaborations in the pharmaco-epigenetics space and the potential for strategic partnerships following the validation of its Nu.Q Lung Cancer Test. Additionally, the adoption of its Nu.Q Discover biomarkers by over 1,000 veterinary hospitals in Japan highlights strong market interest and expands its revenue potential in the animal diagnostics sector. The company’s proprietary Nucleosomics platform not only enhances research capabilities but also accelerates biomarker discovery, contributing positively to its overall financial outlook.
Bears say
VolitionRX Ltd. is actively working on developing blood tests using its Nucleosomics platform, specifically targeting the high false-positive rates associated with low-dose computed tomography (LDCT) screenings for pulmonary nodules. However, the reliance on addressing these prevalent diagnostic issues does not guarantee successful market adoption or revenue generation, particularly when faced with competition and existing alternative diagnostic methods. Financially, the company's challenge lies in translating research and development into commercially viable products, amid uncertainties surrounding regulatory approval and potential market penetration.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares